Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Pharmacological Reviews
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Pharmacological Reviews

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit Pharm Rev on Facebook
  • Follow Pharm Rev on Twitter
  • Follow ASPET on LinkedIn
Review ArticleReview

International Union of Pharmacology. XXXIV. Lysophospholipid Receptor Nomenclature

Jerold Chun, Edward J. Goetzl, Timothy Hla, Yasuyuki Igarashi, Kevin R. Lynch, Wouter Moolenaar, Susan Pyne and Gabor Tigyi
Pharmacological Reviews June 2002, 54 (2) 265-269; DOI: https://doi.org/10.1124/pr.54.2.265
Jerold Chun
1 2 3 4 5 6 7 8
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Edward J. Goetzl
1 2 3 4 5 6 7 8
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Timothy Hla
1 2 3 4 5 6 7 8
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yasuyuki Igarashi
1 2 3 4 5 6 7 8
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kevin R. Lynch
1 2 3 4 5 6 7 8
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wouter Moolenaar
1 2 3 4 5 6 7 8
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susan Pyne
1 2 3 4 5 6 7 8
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gabor Tigyi
1 2 3 4 5 6 7 8
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The lysophospholipids, lysophosphatidic acid (LPA) and sphingosine 1-phosphate (S1P), are now recognized as important extracellular signaling molecules. These lipid mediators are pleiotropic; among the most common cellular responses are mitogenesis, cell survival (anti-apoptosis), inhibition of adenylyl cyclase and calcium mobilization. Physiologic events associated with these mediators include platelet aggregation, vasopressor activity, wound healing, immune modulation, and angiogenesis. Many of the actions of LPA and S1P are mediated through a set of eight G protein-coupled receptors. Five of these are S1P-prefering while the remaining three are LPA receptors. These receptors are expressed widely and in aggregate signal through a variety of heterotrimeric G proteins. The lysophospholipid receptor family is referred to commonly as the “Edg” group (e.g., Edg-1, Edg-2, etc.). Herein, the molecular pharmacology of the lysophospholipid receptors is reviewed briefly, and a rational nomenclature for LPA and S1P receptors that is consistent with the International Union of Pharmacology guidelines is proposed.

I. Introduction

Lysophosphatidic acid (LPA1) and sphingosine 1-phosphate (S1P) are now known to be pleiotropic extracellular signaling molecules. The first report of lysophosphatidic acid-evoked responses from tissue described its activity as a vasopressor (Tokumura et al., 1978). Subsequently, LPA was found to be proliferative for cultured cells (van Corven et al., 1989)—an observation that spurred much subsequent investigation. S1P has also been shown to be proliferative for cultured cells (Zhang et al., 1991). Investigations into numerous aspects of lysophospholipid (LPL) signaling led to the realization that many LPL-evoked events are mediated by heterotrimeric G proteins, thus predicting the existence of LPL G protein-coupled receptors (GPCRs).

II. Discovery of Lysophospholipid Receptors

The receptor cluster that contains the eight LPL receptors has the colloquial name “Edg” (an acronym for endothelialdifferentiation gene). The name Edg (or EDG) was coined in 1990 by Hla and Maciag to describe a set of immediate early response gene products cloned from human umbilical vein endothelial cells; Edg-1 was found to be a rhodopsin family GPCR (Hla and Maciag, 1990). A GPCR that was 50% identical was reported in 1993 (“AGR16”; Okazaki et al., 1993) and independently the following year (“H218”; MacLennan et al., 1994). The Edg name appeared again in 1995 (Edg-2) to describe a third, more distantly related, GPCR (Masana et al., 1995). The orthologous (species homolog) mouse GPCR was then described (“rec1.3”; Macrae et al., 1996). The other five members of the cluster were named in order of their appearance as Edg-3, Edg-4, Edg-6, Edg-7, and Edg-8 and eventually AGR16/H218 became commonly known as Edg-5.

A seminal event in the LPL field occurred when Chun and colleagues discovered that mouse Edg-2 (they called it “vzg-1”) is an LPA receptor (Hecht et al., 1996). This was followed quickly by three reports that Edg-3 and Edg-1 are S1P-preferring receptors (An et al., 1997; Lee et al., 1998; Zondag et al., 1998). Within several years, reports from a number of groups established that there are eight Edg receptor genes in the human genome. Five of these encode S1P receptors (Edg-1, -3, -5, -6, and -8) whereas the remaining three encode LPA receptors (Edg-2, -4, and -7). The S1P receptors share about 50% identical amino acids whereas the LPA receptors have about 55% sequence identity. The subclusters are about 35% identical. A maximum parsimony tree showing graphically the relationship among the LPL receptors and the distantly related platelet-activating factor receptor is shown as the Fig. 1. Different aspects of LPL biochemistry, physiology, and cell biology are discussed in a variety of recent review articles (Hla, 2001; Tigyi, 2002) (also for review, see Chun et al., 1999; Moolenaar, 1999; Pyne and Pyne, 2000;Fukushima et al., 2001; Hla et al., 2001).

Figure 1
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1

The single maximum parsimony tree of the human LPL receptor amino acid sequences and the human platelet-activating factor receptor sequence. This unrooted tree was built with PROTPARS (available at www.evolution.genetics.washington.edu) in PHYLIP package (5 runs, 10–23 jumbles per run).

III. Receptor Nomenclature

Although the Edg acronym proved prescient for Edg-1 (Hla et al., 2001), this name has little relevance to the other seven receptors in the family. The names AGR16, H218, vzg-1, rec1.3, etc. are trivial also. Furthermore, the Edg name has been applied to unrelated proteins and thus is a possible source of confusion (Hla et al., 1997). A rational, alternate nomenclature has been proposed (Chun et al., 1999), but this scheme has not been embraced, and it is not consistent with IUPHAR guidelines (Humphrey et al., 2000; Ruffolo et al., 2000). According to those guidelines, a receptor is to be named with the abbreviation for the natural agonist with the highest potency, followed by a subscripted arabic number. Because the NC-IUPHAR Subcommittee on Lysophospholipid Receptors recommends that sphingosine 1-phosphate be abbreviated S1P (rather than SPP or Sph-P), Edg-1 becomes S1P1 and Edg-2 becomes LPA1. The subcommittee decided further that the order of numbering is to reflect the chronology of the publication of receptor sequence (regardless of whether the ligand was known at that time), thus Edg-5/H218/AGR16 becomes S1P2, etc. Table 1 lists recommended LPL receptor names, the IUPHAR Receptor Code (Humphrey et al., 2000), and previous LPL receptor names. LPL receptor splice variants, such as that described for the human LPA3 receptor (Fitzgerald et al., 2000), are not named individually since they have not been shown to have distinct pharmacologic properties. The recommended receptor nomenclature is flexible in that it readily accommodates additional LPL GPCRs, regardless of their similarity to the Edg cluster. Additional LPA receptors (Guo et al., 1996) as well as sphingosylphosphorylcholine (SPC) (Xu et al., 2000) and lysophosphatidylcholine (LPC) (Kabarowski et al., 2001) receptors have been suggested. However, until data verifying these identifications is published independently, the NC-IUPHAR Subcommittee on Lysophospholipid Receptors has decided against including these putative LPL receptors at this juncture.

View this table:
  • View inline
  • View popup
Table 1

LPL receptors

IV. Nonhuman Lysophospholipid Receptors

Current evidence suggests the existence of an orthologous set of eight LPL receptor genes in rodents; presumably this will hold true for all mammals. An analysis of the nearly complete Takifugu rubripes (Japanese puffer fish) genome reveals at least ten LPL receptor-like genes—four LPA receptor-like and six S1P receptor-like (K. R. Lynch, unpublished observation). There is little, if any, evidence for LPL receptors in any nonvertebrate species. The IUPHAR nomenclature should be applied to mammalian receptors only because the nonmammalian LPL receptors are so distant as to make identification of orthologs problematic. For example, the zebrafish gene, miles apart (Mil)—a mutation of which results in cardiac bifida (Kupperman et al., 2000)—has been suggested to be orthologous to the human S1P2 receptor because of their 60% identical amino acids. However, this is an insufficient basis to assume the correspondence in function between Mil and S1P2 that is predicted for orthologous genes—and the deletion of the S1P2 gene in mice does not result in detectable abnormalities in cardiac development (MacLennan et al., 2001). The exception to the rule is the LPA1receptor, which shows a high degree of sequence conservation among chicken, fish, amphibians (Xenopus), and mammals. Remarkably, the LPA1 receptor from all these species shares >90% identical amino acids, with most of the mismatch at the amino-terminal regions. The other LPL receptors—and GPCRs in general—share only 40 to 70% identical amino acids when sequences from disparate vertebrate species are compared. The extraordinary sequence conservation of the LPA1 receptor leads one to wonder whether this protein is serving some function beyond binding LPA and signaling heterotrimeric G proteins.

V. Lysophospholipid Receptor Ligands

A synthetic chemistry focused on LPL receptors is currently underway, but there are very few defining ligands at present. For both LPA and S1P, the addition of a head group (e.g., choline) to form a phosphate diester or the replacement of the phosphate with an alcohol result in decreases in potency of several log orders (for review, seeLynch and Macdonald, 2001). Conversely, the degree of saturation of the alkyl moiety of either ligand has little effect on potency, that is dihydro S1P is equipotent to S1P and 16:0 LPA is equipotent to 18:1 LPA—with the important exception of the LPA3receptor, which has a pronounced preference for unsaturated LPAs (Bandoh et al., 1999; Im et al., 2000b). Recently, two LPA receptor antagonists have been described. The first is di-octyl glycerol pyrophosphate, which is a competitive antagonist of the LPA3 receptor with a reportedK i of 100 nM (Fisher et al., 2001). The second, which is an N-oleoyl ethanolamide phosphate that is substituted at the second carbon with a benzyl-4-oxybenzyl moiety, is a competitive antagonist of the LPA1 and LPA3 receptors (K i values 125 and 430 nM, respectively). The opposite enantiomer (R) of the latter compound is about 10-fold more potent in blocking the LPA3 receptor, but is an agonist at the LPA1 site (Heise et al., 2001).

There are currently no available S1P receptor selective agonists or antagonists, but the availability of a radioligand binding assay allows the measurement of ligand affinities at recombinant S1P receptors. Although no one group has yet reported comparative binding analyses of all five S1P receptors, the reportedK D values from different laboratories (obtained by equilibrium binding methods) are in the range of 1 to 60 nM, with the S1P4 receptor having the lowest affinity for S1P (van Brocklyn et al., 2000). A model of the S1P1 receptor ligand binding domain has been proposed (Parrill et al., 2000) with a specific emphasis on the Arg-Glu-Gly motif that is present at the exofacial aspect of the third transmembrane-spanning region of all S1P receptors. An obvious prediction is that side chains of the arginine and glutamate residues interact with the vicinal phosphate and amino groups on S1P. This prediction was tested by mutating the Arg-Glu-Gly motif to that conserved among LPA receptors (Arg-Gln-Gly), and the ligand selectivity of the mutant receptors (S1P1 and LPA1) was found to switch in concert with the mutations (Wang et al., 2001). Thus the hydrophilic “head group” of the lysophospholipids is thought to interact with the amino-terminal aspect of the third transmembrane region. However, the areas of the receptor protein that interact with the hydrophobic “tail” of the LPL ligands are uncertain at present.

VI. Lysophospholipid Receptor Gene Knockouts

The function of the LPL receptors has been explored by germ line ablation of the individual receptor genes. In addition to the zebrafishmiles apart mutation mentioned above, the LPA1, S1P1, S1P2, and S1P3 receptor genes in mice have been “knocked out”. The S1P3 receptor −/− mice are without obvious phenotype (Ishii et al., 2001) whereas some 20% of S1P2 receptor −/− mice were reported to experience at least one epileptic seizure between 3 and 6 weeks of age (MacLennan et al., 2001). The S1P1 receptor −/− mice die about gestational age E13 from failure of the vasculature to become invested with smooth muscle (Liu et al., 2000). Mice lacking a functional LPA1 receptor gene are born but have a defect in their suckling behavior—apparently because of a defect in olfaction—that in turn results in increased neonatal mortality and stunted growth of survivors (Contos et al., 2000). Analyses of the phenotypes of mice with the remaining four LPL receptor genes ablated are not yet published but are underway in several laboratories.

VII. Lysophospholipid Receptor Expression

Finally, the expression of each of the LPL receptor genes has been examined in rodents and humans. The general lack of high quality antibodies and high affinity radiolabeled ligands necessitates inferring receptor expression by measurement of accumulation of the cognate mRNAs. The LPA1 receptor mRNA is restricted largely (in rodents) to myelinating glia including Schwann cells, but before birth the LPA1 mRNA is abundant in developing cortical neurons (Hecht et al., 1996; Weiner et al., 1998). However, the human LPA1 receptor mRNA is reported to be found in the extract of many tissues including heart, brain, colon, small intestine, and prostate but not in extracts of liver, lung, thymus, or leukocytes (An et al., 1998). LPA2 receptor expression is most prominent in leukocytes (An et al., 1998) whereas the LPA3receptor mRNA is found in extracts of kidney, lung, heart, pancreas, and prostate (Bandoh et al., 1999; Im et al., 2000b). In mouse, all three LPA receptor type mRNAs are prominent in testes extracts (Contos and Chun, 2001). Among the S1P receptors, the S1P1 receptor type is expressed ubiquitously as is the S1P3 receptor (Yamaguchi et al., 1996). The S1P2 receptor is expressed in embryonic brain and postnatally in brain, heart, lung, stomach, intestine, and adrenal gland (Okazaki et al., 1993; MacLennan et al., 1994). The S1P4 receptor is unusual in that its expression is confined to lymphoid tissue (Gräler et al., 1998). Finally, the S1P5 receptor mRNA is found in white matter and spleen in rats (Im et al., 2000a).

VIII. Conclusion

Although there is little likelihood that additional Edg cluster receptor genes will be found, their identification represents only the end of the beginning. The importance of the LPL mediators is evidenced by the steady increase of publications focused on these molecules. The application of selective ligands under development that mimic or block LPLs at their receptors will surely reveal a rich pathophysiology controlled by this signaling system.

Footnotes

  • Address correspondence to: Dr. Kevin R. Lynch, Subcommittee Chair, Pharmacology Box 800735, University of Virginia Health System, 1300 Jefferson Park Avenue, Charlottesville, VA 22908.

  • Center for Vascular Biology, Department of Physiology, University of Connecticut, 263 Farmington Ave., Farmington, CT 06030; Yasuyuki Igarashi, Department of Biomembrane and Biofunctional Chemistry, Hokkaido University, Nishi 6, Kita 12, Kita-ku, Sapporo 060-0812, Japan; Kevin R. Lynch (Chair), Department of Pharmacology, Box 800735, University of Virginia, 1300 Jefferson Park Ave., Charlottesville, VA 22908-0735; Wouter H. Moolenaar, Division of Cellular Biochemistry, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; Susan Pyne, Department of Physiology and Pharmacology, University of Strathclyde, 27 Taylor St., Glasgow G4 ONR, Scotland; and Gabor Tigyi, Department of Physiology, University of Tennessee, 894 Union Ave., Memphis, TN 38163.

  • Composition of the NC-IUPHAR Subcommittee on Lysophospholipid Receptors: Jerold Chun, Merck Research Laboratories, 505 Coast Boulevard South, La Jolla, CA 92037; Edward J. Goetzl, Department of Medicine, University of California, U88B Box 0711, 533 Parnassus Ave., San Francisco, CA 94143-0711; Timothy Hla,

Abbreviations

LPA
lysophosphatidic acid
S1P
sphingosine 1-phosphate
LPL
lysophospholipid
GPCR
G protein-coupled receptor
Edg
endothelial differentiation gene
NC-IUPHAR
International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification
SPC
sphingosylphosphorylcholine
LPC
lysophosphatidylcholine
  • The American Society for Pharmacology and Experimental Therapeutics

References

  1. ↵
    1. An S,
    2. Bleu T,
    3. Hallmark OG, and
    4. Goetzl EJ
    (1998) Characterization or a novel subtype of human G protein-coupled receptor for lysophosphatidic acid. J Biol Chem 273:7907–7910.
    OpenUrl
  2. ↵
    1. An S,
    2. Bleu T,
    3. Huang W,
    4. Hallmark OG,
    5. Coughlin SR, and
    6. Goetzl EJ
    (1997) Identification of cDNAs encoding two G protein-coupled receptors for lysophospholipids. FEBS Lett 417:279–282.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Bandoh K,
    2. Aoki J,
    3. Hosono H,
    4. Kobayashi S,
    5. Kobayashi T,
    6. Murakami-Murofushi K,
    7. Tsujimoto M,
    8. Arai H, and
    9. Inoue K
    (1999) Molecular cloning and characterization of a novel human G protein-coupled receptor, EDG7, for lysophosphatidic acid. J Biol Chem 274:27776–27785.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Chun J,
    2. Contos JJA, and
    3. Munroe D
    (1999) A growing family of receptor genes for lysophosphatidic acid (LPA) and other lysophospholipids (LPs). Cell Biochem Biophys 30:213–242.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Contos JJA and
    2. Chun J
    (2001) The mouse lpA3/jEdg7 lysophosphatidic acid receptor gene: genomic structure, chromosomal localization and expression pattern. Gene (Amst) 267:243–253.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Contos JJA,
    2. Fukushima N,
    3. Weiner JA,
    4. Kaushai D, and
    5. Chun J
    (2000) Requirement for the lpA1 lysophosphatidic acid receptor gene in normal suckling behavior. Proc Natl Acad Sci USA 97:13384–13389.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Fisher DJ,
    2. Nusser N,
    3. Virag T,
    4. Yokoyama K,
    5. Wang D,
    6. Baker DL,
    7. Bautista D,
    8. Parrill AL, and
    9. Tigyi G
    (2001) Short-chain phosphatidates are subtype-selective antagonists of lysophosphatidic acid receptors. Mol Pharmacol 60:776–784.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Fitzgerald LR,
    2. Dytko GM,
    3. Sarau HM,
    4. Mannan IJ,
    5. Ellis C,
    6. Lane PA,
    7. Tan KB,
    8. Murdoch PR,
    9. Wilson S,
    10. Bergsma DJ,
    11. et al.
    (2000) Identification of an EDG7 variant, HOFNH30, a G protein-coupled receptor for LPA. Biochem Biophys Res Comm 273:805–810.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Fukushima N,
    2. Ishii I,
    3. Contos JJA,
    4. Weiner JA, and
    5. Chun J
    (2001) Lysophospholipid receptors. Annu Rev Pharmacol Toxicol 41:507–534.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Gräler MH,
    2. Bernhardt G, and
    3. Lipp M
    (1998) EDG6, a novel G protein-coupled receptor related to receptors for bioactive lysophospholipids, is specifically expressed in lymphoid tissue. Genomics 53:164–169.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Guo Z,
    2. Liliom K,
    3. Fisher DJ,
    4. Bathurst IC,
    5. Tomei ID,
    6. Kiefer MC, and
    7. Tigyi G
    (1996) Molecular cloning of a high affinity receptor for the growth factor-like mediator lysophosphatidic acid from Xenopus oocytes. Proc Natl Acad Sci USA 93:14367–14372.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Hecht JH,
    2. Weiner JA,
    3. Post SR, and
    4. Chun J
    (1996) Ventricular zone gene-1 (vzg-1) encodes a lysophosphatidic acid receptor expressed in neurogenic regions of the developing cerebral cortex. J Cell Biol 135:1071–1083.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Heise CE,
    2. Santos WL,
    3. Schreihofer AM,
    4. Heasley BH,
    5. Mukhin YV,
    6. Macdonald TL, and
    7. Lynch KR
    (2001) Activity of 2-substituted LPA analogs at LPA receptors: discovery of a LPA1/LPA3 receptor antagonist. Mol Pharmacol 60:1173–1180.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Hla T
    (2001) Sphingosine 1-phosphate receptors. Prostaglandins Other Lipid Mediat 64:135–142.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Hla T,
    2. Lee MJ,
    3. Ancellin N,
    4. Paik JK, and
    5. Kluk MJ
    (2001) Lysophospholipids—receptor revelations. Science (Wash DC) 294:1875–1878.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Hla T and
    2. Maciag TJ
    (1990) An abundant transcript induced in differentiating human endothelial cells encodes a polypeptide with structural similarities to G protein coupled receptors. J Biol Chem 265:9308–9313.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    1. Hla T,
    2. Zimrin AB,
    3. Evans M,
    4. Ballas K, and
    5. Maciag T
    (1997) The immediate-early gene product MAD-3/EDG-3/IkappaB alpha is an endogenous modulator of fibroblast growth factor-1 (FGF-1) dependent human endothelial cell growth. FEBS Lett 414:419–424.
    OpenUrlCrossRefPubMed
  18. ↵
    1. Humphrey PPA,
    2. Barnard EA,
    3. Bonner TI,
    4. Catterall WA,
    5. Dollery CT,
    6. Fredholm BB,
    7. Godfraind T,
    8. Harmar AJ,
    9. Langer SZ,
    10. Lauder V,
    11. et al.
    (2000) The IUPHAR receptor code. The IUPHAR Compendium of Receptor Characterization and Classification (IUPHAR Media, London), 2nd ed, pp 9–23.
  19. ↵
    1. Im DS,
    2. Heise CE,
    3. Ancellin N,
    4. O'Dowd BF,
    5. Shei GJ,
    6. Heavens RP,
    7. Rigby MR,
    8. Hla T,
    9. Mandala S,
    10. McAllister G,
    11. et al.
    (2000a) Characterization of a novel sphingosine 1-phosphate receptor, Edg-8. J Biol Chem 275:14281–14286.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Im DS,
    2. Heise CE,
    3. Harding MA,
    4. George SR,
    5. O'Dowd BF,
    6. Theodorescu D, and
    7. Lynch KR
    (2000b) Molecular cloning and characterization of a lysophosphatidic acid receptor, Edg-7, expressed in prostate. Mol Pharmacol 57:753–759.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. Ishii I,
    2. Friedman B,
    3. Ye X,
    4. Kawamura S,
    5. McGiffert C,
    6. Contos JJ,
    7. Kingsbury MA,
    8. Zhang G,
    9. Heller Brown J, and
    10. Chun J
    (2001) Selective loss of sphingosine 1-phosphate signaling with no obvious phenotypic abnormality in mice lacking its G protein-coupled receptor, LP(B3)/EDG-3. J Biol Chem 276:33697–33704.
    OpenUrlAbstract/FREE Full Text
  22. ↵
    1. Kabarowski JH,
    2. Zhu K,
    3. Le LQ,
    4. Witte ON, and
    5. Xu Y
    (2001) Lysophosphatidylcholine as a ligand for the immunoregulatory receptor G2A. Science (Wash DC) 293:702–705.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Kupperman E,
    2. An S,
    3. Osborne H,
    4. Waldron S, and
    5. Stainier DYR
    (2000) A sphingosine 1-phosphate receptor regulates cell migration during vertebrate heart development. Nature (Lond) 406:192–195.
    OpenUrlCrossRefPubMed
  24. ↵
    1. Lee MJ,
    2. van Brocklyn JR,
    3. Thangada S,
    4. Liu CH,
    5. Hand AR,
    6. Menzeleev R,
    7. Spiegel S, and
    8. Hla T
    (1998) Sphingosine 1-phosphate as a ligand for the G protein-coupled receptor EDG-1. Science (Wash DC) 279:1552–1555.
    OpenUrlAbstract/FREE Full Text
  25. ↵
    1. Liu Y,
    2. Wada R,
    3. Yamashita T,
    4. Mi Y,
    5. Deng CX,
    6. Hobson JP,
    7. Rosenfeldt HM,
    8. Nava VE,
    9. Chae SS,
    10. Lee MJ,
    11. et al.
    (2000) Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation. J Clin Investig 106:951–961.
    OpenUrlCrossRefPubMed
  26. ↵
    1. Lynch KR and
    2. Macdonald TL
    (2001) Structure activity relationships of lysophospholipid mediators. Prostglandins Other Lipid Mediat 64:33–45.
    OpenUrl
  27. ↵
    1. MacLennan AJ,
    2. Browe CS,
    3. Gaskin AA,
    4. Lado DC, and
    5. Shaw G
    (1994) Cloning and characterization of a putative G protein coupled receptor potentially involved in development. Mol Cell Neurosci 5:201–209.
    OpenUrlCrossRefPubMed
  28. ↵
    1. MacLennan AJ,
    2. Carney PR,
    3. Zhu WJ,
    4. Chaves AH,
    5. Garcia J,
    6. Grimes JR,
    7. Anderson KJ,
    8. Roper SN, and
    9. Lee N
    (2001) An essential role for the H218/AGR16/Edg-5/LPB2 sphingosine 1-phosphate receptor in neuronal excitability. Eur J Neurosci 14:203–209.
    OpenUrlCrossRefPubMed
  29. ↵
    1. Macrae AD,
    2. Premont RT,
    3. Jaber M,
    4. Peterson AS, and
    5. Lefkowitz RJ
    (1996) Cloning, characterization and chromosomal localization of rec1.3, a member of the G-protein-coupled receptor family highly expressed in brain. Mol Brain Res 42:245–254.
    OpenUrlCrossRefPubMed
  30. ↵
    1. Masana MI,
    2. Brown RC,
    3. Pu H,
    4. Gurney ME, and
    5. Dubocovich ML
    (1995) Cloning and characterization of a new member of the G protein-coupled receptor EDG family. Receptors Channels 3:255–262.
    OpenUrlPubMed
  31. ↵
    1. Moolenaar WH
    (1999) Bioactive lysophospholipids and their G protein-coupled receptors. Exp Cell Res 253:230–238.
    OpenUrlCrossRefPubMed
  32. ↵
    1. Okazaki H,
    2. Ishizaka N,
    3. Sakurai T,
    4. Kurokawa K,
    5. Goto K,
    6. Kumada M, and
    7. Takuwa Y
    (1993) Molecular cloning of a novel putative G protein coupled receptor expressed in the cardiovascular system. Biochem Biophys Res Comm 190:1104–1109.
    OpenUrlCrossRefPubMed
  33. ↵
    1. Parrill AL,
    2. Wang DA,
    3. Bautista DL,
    4. van Brocklyn JR,
    5. Lorincz Z,
    6. Fischer DJ,
    7. Baker DL,
    8. Liliom K,
    9. Spiegel S, and
    10. Tigyi GJ
    (2000) Identification of Edg1 receptor residues that recognize sphingosine 1-phosphate. J Biol Chem 275:39379–39384.
    OpenUrlAbstract/FREE Full Text
  34. ↵
    1. Pyne S and
    2. Pyne N
    (2000) Sphingosine 1-phosphate signalling in mammalian cells. Biochem J 349:385–402.
    OpenUrlCrossRefPubMed
  35. ↵
    1. Ruffolo RR,
    2. Humphrey PPA,
    3. Watson SP, and
    4. Spedding M
    (2000) Revised NC-IUPHAR recommendations for nomenclature of receptors. The IUPHAR Compendium of Receptor Characterization and Classification (IUPHAR Media, London), 2nd ed, pp 7–8.
  36. ↵
    1. Tigyi G
    (2002) Biochim Biophys Acta, in press.
  37. ↵
    1. Tokumura A,
    2. Fukuzawa K,
    3. Akamatsu Y,
    4. Yamada S,
    5. Suzuki T, and
    6. Tsukatani H
    (1978) Identification of vasopressor phospholipid in crude soybean lecithin. Lipids 13:468–472.
    OpenUrlCrossRefPubMed
  38. ↵
    1. van Brocklyn JR,
    2. Gräler MH,
    3. Bernhardt G,
    4. Hobson JP,
    5. Lipp M, and
    6. Spiegel S
    (2000) Sphingosine 1-phosphate is a ligand for the G protein-coupled receptor EDG-6. Blood 95:2624–2629.
    OpenUrlAbstract/FREE Full Text
  39. ↵
    1. van Corven EJ,
    2. Groenink A,
    3. Jalink K,
    4. Eichholtz T, and
    5. Moolenaar WH
    (1989) Lysophosphatidate-induced cell proliferation: identification and dissection of signaling pathways mediated by G proteins. Cell 59:45–54.
    OpenUrlCrossRefPubMed
  40. ↵
    1. Wang DA,
    2. Lorincz Z,
    3. Bautista DL,
    4. Liliom K,
    5. Tigyi G, and
    6. Parrill AL
    (2001) A single amino acid determines lysophospholipid specificity of the S1P1 (EDG1) and LPA1 (EDG2) phospholipid growth factor receptors. J Biol Chem 276:49213–49220.
    OpenUrlAbstract/FREE Full Text
  41. ↵
    1. Weiner JA,
    2. Hecht JH, and
    3. Chun J
    (1998) Lysophosphatidic acid receptor gene vzg-1/lpA1/edg-2 is expressed by mature oligodendrocytes during myelination in the postnatal murine brain. J Comp Neurol 398:587–598.
    OpenUrlCrossRefPubMed
  42. ↵
    1. Xu Y,
    2. Zhu K,
    3. Hong G,
    4. Wu W,
    5. Baudhuin LM,
    6. Xiao YJ, and
    7. Damron DS
    (2000) Sphingophosphorylcholine is a ligand for ovarian cancer G protein coupled receptor 1. Nat Cell Biol 2:261–267.
    OpenUrlCrossRefPubMed
  43. ↵
    1. Yamaguchi F,
    2. Tokuda M,
    3. Hatase O, and
    4. Brenner S
    (1996) Molecular cloning of the novel human G protein-coupled receptor (GPCR) gene mapped on chromosome 9. Biochem Biophys Res Comm 227:608–614.
    OpenUrlCrossRefPubMed
  44. ↵
    1. Zhang H,
    2. Desai NN,
    3. Olivera A,
    4. Seki T,
    5. Brooker G, and
    6. Spiegel S
    (1991) Sphingosine 1-phosphate, a novel lipid, involved in cellular proliferation. J Cell Biol 114:155–167.
    OpenUrlAbstract/FREE Full Text
  45. ↵
    1. Zondag GCM,
    2. Postma FR,
    3. van Ettern I,
    4. Verlaan I, and
    5. Moolenaar WH
    (1998) Sphingosine 1-phosphate signalling through the G protein coupled receptor, Edg-1. Biochem J 330:605–609.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

Pharmacological Reviews: 54 (2)
Pharmacological Reviews
Vol. 54, Issue 2
1 Jun 2002
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Pharmacological Reviews article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
International Union of Pharmacology. XXXIV. Lysophospholipid Receptor Nomenclature
(Your Name) has forwarded a page to you from Pharmacological Reviews
(Your Name) thought you would be interested in this article in Pharmacological Reviews.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Review ArticleReview

International Union of Pharmacology. XXXIV. Lysophospholipid Receptor Nomenclature

Jerold Chun, Edward J. Goetzl, Timothy Hla, Yasuyuki Igarashi, Kevin R. Lynch, Wouter Moolenaar, Susan Pyne and Gabor Tigyi
Pharmacological Reviews June 1, 2002, 54 (2) 265-269; DOI: https://doi.org/10.1124/pr.54.2.265

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Review ArticleReview

International Union of Pharmacology. XXXIV. Lysophospholipid Receptor Nomenclature

Jerold Chun, Edward J. Goetzl, Timothy Hla, Yasuyuki Igarashi, Kevin R. Lynch, Wouter Moolenaar, Susan Pyne and Gabor Tigyi
Pharmacological Reviews June 1, 2002, 54 (2) 265-269; DOI: https://doi.org/10.1124/pr.54.2.265
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • I. Introduction
    • II. Discovery of Lysophospholipid Receptors
    • III. Receptor Nomenclature
    • IV. Nonhuman Lysophospholipid Receptors
    • V. Lysophospholipid Receptor Ligands
    • VI. Lysophospholipid Receptor Gene Knockouts
    • VII. Lysophospholipid Receptor Expression
    • VIII. Conclusion
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Induction of Drug Metabolism: The Role of Nuclear Receptors
  • International Union of Pharmacology. XXXIX. Compendium of Voltage-Gated Ion Channels: Sodium Channels
  • International Union of Pharmacology. XL. Compendium of Voltage-Gated Ion Channels: Calcium Channels
Show more REVIEW

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Pharmacological Reviews
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacology Research & Perspectives
ISSN 1521-0081 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics